A suit filed for a trio of anti trust by Glaxo Smith Kline has been upheld by a Senior U.S. District Judge Anita B. Brody without giving importance to the arguments by GSK lawyers. The claim of the Plaintiffs is that GSK improperly influenced the Food and Drug administration’s process and set extremely rigorous requirements for the launch of cheaper generic versions of the drug Flonase by others and that is how GSK’s sales of Flonase peaked at $1.3 billion in 2005. Copies of the 31-page opinion in In re Flonase Antitrust Litigation are available from The Legal Intelligencer.
Read the original article here: